# enriching | engaging | empowering

Check for updates

#### **Original Article**

# **Effects of combination of me[latonin and](http://crossmark.crossref.org/dialog/?doi=10.18502/ijrm.v22i7.16961&domain=pdf&date_stamp=2018-01-27) L-carnitine on in vitro maturation in mouse oocytes: An experimental study**

**Corresponding Author:**

Fariba Zafari; Cellular and Molecular Research Center, Research Institute for Prevention of Non-communicable Disease, Qazvin University of Medical Sciences, Shahid Bahonar Blvd., Qazvin, Iran.

**Postal Code:** 37197–59811

**Tel:** (+98) 9125604503

**Email:** f.zafari@qums.ac.ir

#### **ORCID:**

*https://orcid.org/0000-0001-6673-278X*

**Received:** 30 September 2023 **Revised:** 18 March 2024 **Accepted:** 11 June 2024

#### **Production and Hosting by Knowledge E**

Chegini *et al*. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original au[thor and source are](https://creativecommons.org/licenses/by/4.0/) [credited.](https://creativecommons.org/licenses/by/4.0/)

Editor-in-Chief: Aflatoonian Abbas M.D. **Raziye Chegini<sup>1</sup> M.Sc., Morteza Sadeghi<sup>2</sup> Ph.D., Sadegh Shirian3, 4 Ph.D., Fatemeh Sabbaghziarani<sup>5</sup> Ph.D., Ehsan Aali<sup>5</sup> Ph.D., Pouriya Soleimani<sup>6</sup> B.Sc., Mohammad Reza Ashtari Majelan<sup>5</sup> M.Sc., Fariba Zafari<sup>5</sup> Ph.D., Shahram Darabi<sup>5</sup> Ph.D.**

<sup>1</sup>Department of Anatomical Sciences, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

<sup>2</sup> Human Genetic Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. <sup>3</sup>Department of Pathology, School of Veterinary Medicine, Shahrekord University, Shahrekord, Iran.

<sup>4</sup>Shiraz Molecular Pathology Research Center, Dr. Daneshbod Path Lab, Shiraz, Iran.

<sup>5</sup>Cellular and Molecular Research Center, Research Institute for Prevention of Non-communicable Disease, Qazvin University of Medical Sciences, Qazvin, Iran.

<sup>6</sup> Department of Nursing, Faculty of Nursing and Midwifery, Qazvin University of Medical Sciences, Qazvin, Iran.

#### **Abstract**

**Background:** Melatonin and L-carnitine are free radical scavengers with antiapoptotic and antioxidant properties that improve oocyte development.

**Objective:** This study aimed to find the possible effect of combining 2 antioxidant agents of melatonin and L-carnitine on oocyte morphology, maturation, apoptosis, and expression of bone morphogenetic protein 15 (*BMP-15*) and growth differentiation factor 9 (*GDF-9*) genes in a mice model.

**Materials and Methods:** To overstimulation, 60 female NMRI mice were injected intraperitoneally using mare serum gonadotropin. On day 2 post-injection, 70 cumulus-oocyte complexes were collected from each mouse. The collected oocytes randomly were then divided into 4 groups including, the control, melatonin, L-carnitine, and melatonin + L-carnitine groups. The morphology and maturation rate of the oocytes was evaluated using a light microscope. Apoptosis was identified by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay and the expression of *BMP-15* and growth and differentiation factor *GDF-9* genes was also evaluated by real-time polymerase chain reaction.

**Results:** Oocyte diameter significantly was increased in combination treatment of L-carnitine and melatonin compared to other groups ( $p < 0.05$ ). L-carnitine group showed the highest mean percentage of oocyte cytoplasmic pattern. Results of the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling indicated that the lowest apoptosis rate belonged to the melatonin + L-carnitine group. Moreover, the combination groups showed the highest number of oocytes and maturation rate. The *BMP-15* and *GDF-9* genes were significantly upregulated in all treatment groups compared to the control group. **Conclusion:** Our results suggested a combination of melatonin + L-carnitine administration as a more effective choice for in vitro promotion of oocyte maturation.

### **GOPEN ACCESS**

*Key words: In vitro oocyte maturation, Melatonin, L-carnitine.*

**How to cite this article**: Chegini R, Sadeghi M, Shirian S, Sabbaghziarani F, Aali E, Soleimani P, Ashtari Majelan MR, Zafari F, Darabi Sh. "Effects of combination of melatonin and L-carnitine on in vitro maturation in mouse oocytes: An experimental study," *Int J Reprod BioMed* 2024; 22: 527–538. https://doi.org/10.18502/ijrm.v22i7.16961

## **1. Introduction**

In vitro maturation (IVM) is a promising technique for maturation of oocytes in the laboratory (1). The quality of oocytes using IVM techniques is suboptimal, which leads to an increase in embryo developmental abnormalities. Production of high reactive oxygen species (ROS) levels during IVM alters the function of the cultured cells and negatively affects embryo development (2). Excessive production of ROS and further reactions of these radicals with cellular molecules (i.e., proteins, lipids, and DNA) may change the functions of these molecules, causing serious problems, including DNA fragmentation, enzymatic inactivation, and ultimately cell death (3). Therefore, using oxidative homeostasis maintenance can improve the quality of oocytes and oxidative homeostasis maintenance. On the other hand, the quality of embryo development depends on factors that maintain the balance between the production of ROS and antioxidant enzymes (4).

It has also been shown that the culture media can be a source of ROS depending on its composition (5). The bone morphogenetic protein 15 (*BMP-15*) and growth differentiation factor 9 (*GDF-9*) are oocyte-secreted factors. They play an important role in controlling the ovarian function in female reproduction and act as potent regulators of folliculogenesis and ovulation (6). It has been shown that BMP-15 and GDF-9 regulate the function of granulosa cells (GCs) during follicular development. GCs has been shown to contribute to oocyte antioxidant defense against ROS (7).

Melatonin (N-acetyl-5-methoxytryptamine) is a product of the pineal gland that plays several physiological roles, including antioxidant and antiapoptotic activities. Its amphiphilic nature allows this hormone to cross biological membranes to reach subcellular compartments, thereby protecting macromolecules against the deleterious effects of oxidative stress. Oxidant/antioxidant balance within follicles seems crucial for normal oocytes and normal functions of GCs. Accumulating evidence has indicated that melatonin protects these cells from oxidative stress. Based on its concentration in the culture medium, melatonin has been shown to have positive or deleterious effects on embryo development. It can regulate the balance between antioxidant and pro-oxidant activity (8). Melatonin improves oocyte quality by influencing the expression of genes linked to oocyte maturation (such as *BMP-15* and *GDF-9*) in polycystic ovarian syndrome. High melatonin concentrations are thought to offer important support during the IVM process. L-carnitine has also been suggested to be used as a novel noninvasive factor to improve not only oocyte quality also embryonic development due to its antioxidant and antiapoptotic effects (9). It was showed that L-carnitine as a strong supplement has been demonstrated to eliminate the cyclophosphamide induced-destructive and harmful effects during chemotherapy in cancer patients and were significantly upregulated by expression levels of oocyte quality genes, including *GDF-9*. Although studies have reported the antioxidant and antiapoptotic effects of melatonin and L-carnitine alone in oocyte culture environments (9, 10), the combination of melatonin and L-carnitine effects on the quality of embryo development and IVM, as well as apoptosis has yet therefore, the present study investigated the effects of supplementing the IVM culture medium

with antioxidants on morphology, maturation rate, and apoptosis of the oocytes, as well as *BMP-15* and *GDF-9* gene expression in the mice model.

### **2. Materials and Methods**

#### **2.1. Animals**

A total of 60 female NMRI mice (4–6 wk, 25–30 gr) were obtained from the anima house of Qazvin University of Medical Sciences, Qazvin, Iran. Mice were kept in standard condition (22ºC, 12 hr light/dark cycle).

#### **2.2. Superovulation and oocyte collection**

Animals were intraperitoneally injected with 7/5 IU pregnant mare serum gonadotropin (PMSG, Millipore, USA) for superovulation. Over a period of 48 hr postinjection of PMSG, the animals were euthanized. The ovaries were dissected and placed in 1 ml of warm minimum essential medium (MEM) alpha (αMEM) (Gibco, USA). Approximately 70 cumulus-oocyte complexes (COCs) were obtained from each mouse. The COCs were removed from oocytes using an insulin syringe needle under an inverted microscope (Optika, XDS-2, Italy).

**2.3. IVM supplemented with melatonin and L-carnitine supplementation**

After collection, immature COCs (cumulus thickness, compactness granulation, and homogeneity of the ooplasm) were washed 3 times in αMEM, placed in a drop of mineral oil, and incubated at 37°C and 5% CO $_2$  in

base culture medium. αMEM supplemented with 5% fetal bovine serum (Invitrogen, USA), 10% human chorionic gonadotropin (Sigma, Germany), 2 µmol fibroblast growth factor, and epidermal growth factor (Peprotech, USA) were used as a base culture medium (11). For experimental groups, the harvested oocytes were randomly divided into 4 groups and assessed for maturation, morphology, and apoptosis. In the control group (I) COCs were cultured without any antioxidant interaction in base culture medium. In the melatonin alone group (II) the base culture medium was supplemented with 2 µmol melatonin (Sigma, Germany) (12). In the L-carnitine alone group (III) the base culture medium was supplemented with 0.6 mg/ml Lcarnitine (Sigma, Germany) (13). In the melatonin + L-carnitine group (IV) the base culture medium was supplemented with a combination of 0.6 mg/ml L-carnitine plus 2 µmol melatonin. The number of oocytes evaluated in control, melatonin alone, L-carnitine alone, and melatonin + L-carnitine groups was 220, 200, 190, and 245, respectively. After 24 hr, metaphase II (MII) oocytes were identified with the extrusion of polar body (PB) 1, and maturation rates of each group were recorded.

### **2.4. Total oocyte score (TOS)**

The harvested oocytes from all experimental groups were assessed based on the TOS with 6 criteria for oocyte quality, including size, morphology, cytoplasm, zona pellucida (ZP), perivitelline space (PVS), and PB. 3 values were assigned to each parameter: -1 (worst), 0 (average), or +1 (best) (14) (Table I).

**2.5. Oocyte maturation rate and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay**

Oocyte maturation, a unique type of cell division, is different from mitosis. An oocyte is arrested at meiotic prophase I, which contains a large nucleus covered by a nuclear envelope known as the germinal vesicle. Then, following a spike in luteinizing hormone, chromosome condensation gradually happens because of germinal vesicle breakdown. The oocyte enters the metaphase I stage when the chromosomes are completely condensed. In order to prepare for chromosome segregation in the ensuing anaphase I, spindle microtubules attach to the kinetochores and chromosomes align on the metaphase plate during this stage. Oocytes stop at MII after the first PB is excluded. Therefore, the maturation rate of the oocytes was determined based on the extrusion of the first PB. The morphology of all the oocytes was then investigated using an inverted microscope (Optika, XDS-2, Italy) pre- and post-IVM. Images of the oocytes were acquired using a digital camera (Delta Pix, USA). After several washing steps with phosphate-buffered saline (Gibco, USA), all the matured oocytes were fixed in 4% paraformaldehyde (Wako, Japan) to measure the apoptosis rate using TUNEL assay and propidium iodide staining. All the cells were covered with  $H_2O_2$  (Sigma, Germany) twice every 10 min. Oocytes were then incubated with proteinase K for 30 min followed by 10 min incubation in 0.3% Triton X-100 (Sigma, Germany) before incubation in the TUNEL solution (Roche, Germany) for 2 hr at 37°C, according to the manufacturer's instructions. Oocytes of the negative control group were only incubated with a fluorescent solution without exposure to the terminal deoxynucleotidyl transferase enzyme to ensure no labeling activity occurred. Oocytes of the positive control group were incubated with 50 µg/ml DNase I solution (Sigma, Germany) for 1 hr before incubation with TUNEL staining solution. To label the nuclei, all the oocytes were stained with 50 µg/ml propidium iodide (Sigma, Germany) solution for 10 min and considered under a fluorescent microscope (Labomed, USA).

### **2.6. Real-time polymerase chain reaction (PCR)**

#### **2.6.1. RNA extraction and cDNA synthesis**

Total ribonucleic acid (RNA) was extracted from the MII oocytes ( $n = 10$  in each group in 3 repeats) using RNeasy Mini kit (Qiagen, Germany) according to the manufacturer's instructions. The purity of extracted RNAs was qualified using NanoDrop (Thermo Fisher Scientific, USA). For mRNA expression analysis, the extracted RNA was reverse transcribed to cDNA using QuantiNova Reverse Transcription (Qiagen, Germany).

The cDNA was amplified using TB Green Premix Ex Taq II (Takara, Japan), and gene expression was determined with a real-time PCR (Corbett Rotor-Gene 6000). β*-actin* was used as internal control. Each sample was done in triplicate. The quantitative RT-PCR cycle consisted of 95°C for 2 min followed by 45 cycles of amplification (95°C, 59°C, and 95°C for sec, 30 sec, and 1 min, respectively). The relative quantification of *GDF-9* and *BMP-15* gene expression was analyzed using StepOne software V2.0 (Fisher Scientific, Loughborough, UK) and compared to the β*-actin* gene and analyzed using the 2-ΔΔCT method.

The primer sets' sequences were selected from NCBI (Table II).

**Table I.** Total oocyte scoring (TOS)



PVS: Perivitelline space, ZP: Zona pellucida, PB: Polar body





*GDF-9*: Growth differentiation factor 9, *BMP-15*: Bone morphogenetic protein 15

#### **2.7. Ethical considerations**

**2.8. Statistical analysis**

This experimental study was conducted according to the guidelines of Qazvin University of Medical Sciences for Animal Care and approved by the Ethics Committee at Qazvin University of Medical Science, Qazvin, Iran (Code: IR.QUMS.REC.1398.165).

(IBM, SPSS Inc, Chicago, USA). The one-way ANOVA followed by post hoc Tukey and Chi-square tests were used to analyze the comparison of gene expression and morphology, respectively.  $P \le 0.05$  was considered statistically significant.

### **3. Results**

#### **3.1. TOS findings**

All the data were analyzed using Statistical Package for the Social Sciences, version 23.0

No significant differences in ZP thickness were observed between different groups in this study. The ZP thickness of the oocytes of the melatonin + L-carnitine and control groups was  $2.58 \pm 0.12$  µm and 3.34  $\pm$  0.32 µm, respectively (Figure 1a). The oocyte diameter was significantly increased to 67.24  $\pm$  0.5 µm in the melatonin + L-carnitine group compared to the control group with the oocyte diameter of  $62.09 \pm 0.95$  µm (p = 0.003). Oocyte diameter showed no significant change in the melatonin (63.49  $\pm$  0.42) and L-carnitine  $(64.16 \pm 0.9)$  alone groups compared to the control group (Figure 1b). The PVS was significantly expanded in all treatment groups compared to the control group (the melatonin alone,  $p = 0.02$ ; and L-carnitine alone,  $p < 0.001$ ; and melatonin  $+$  L-carnitine groups,  $p < 0.001$ ). However, these changes were not statistically significant between the treatment groups (Figure 1c).

The cytoplasmic pattern of most of the oocytes in the melatonin, L-carnitine, and melatonin + L-carnitine groups fitted the +1 grade compared to control group;  $72 + 12.8$ %, 69  $\pm$  17%, and 80  $\pm$  6.5%, respectively. The highest mean percentage of +1 graded cytoplasmic pattern belonged to the melatonin  $+$  L-carnitine group (Figure 2a). As compared to the control group, most of the PBs in the melatonin, L-carnitine, and melatonin + L-carnitine groups were in the +1 grade. The mean percentages of +1 graded PBs in the melatonin, L-carnitine, and melatonin + L-carnitine groups were  $44 \pm 12\%$ , 47.5  $\pm$  9.8%, and 53.4  $\pm$  14%, respectively (Figure 2b). The mean percentage of the oocyte morphology with grade +1 was higher in the treatment groups than in the control group. The melatonin  $+$  Lcarnitine group presented the highest mean percentage of oocytes with a +1 grade. These percentages for melatonin, L-carnitine, and

melatonin + L-carnitine groups were 77.6  $\pm$ 10.3%, 75  $\pm$  6.5%, and 80  $\pm$  9.8%, respectively (Figure 2c).

### **3.2. Oocyte maturation rate and TUNEL assay**

The oocyte maturation rate was significantly increased in the treatment groups compared to the control group. The highest maturation rate was detected in the melatonin + L-carnitine group (83  $\pm$  6%). The mean percentage of maturation rate in the L-carnitine alone and melatonin alone groups was  $73 + 5.2\%$  and 75  $\pm$  4%, respectively. The apoptosis rate was assessed using the TUNEL assay, and it was reduced in the treatment groups compared to control group. Amongst the treatment groups, the lowest apoptosis rate was seen in the melatonin + L-carnitine group (10  $\pm$  5%). The rate of apoptosis in the L-carnitine alone and melatonin alone groups were  $19 \pm 6.1\%$  and  $16 \pm 3\%$ , respectively (Figure 3). The microscopic images of TUNEL positive and TUNEL negative oocytes in different groups are depicted in figure 4.

#### **3.3.** *BMP-15* **and** *GDF-9* **genes expression**

The gene expression levels of *BMP-15* and *GDF-9* were significantly upregulated in the combination of melatonin and L-carnitine group as well as the melatonin and L-carnitine alone groups compared to the control group (Figure 5). However, the expression levels of both genes showed no significant difference between any 3 treatment groups (Figure 6).



Figure 1. Scoring parameters of oocytes in different groups. A) Zona pellucida, B) Oocyte diameter, and C) Perivitelline space.  $*p = 0.02$ ,  $**$  and  $**$  $p \le 0.001$ , and  $***$  $p = 0.003$  vs control.



**Figure 2.** Scoring parameters of oocytes in different groups. A) Cytoplasm grading, B) Polar body, and C) Oocyte morphology. In all the treated groups, most of the oocytes fitted grade +1 compared to the control group.





**Figure 3.** The graph shows the comparison of the maturation rate of the oocytes (Oocytes [MII] rate was determined based on the extrusion of the first PB) and apoptosis rate. The rate of apoptosis in the treated groups was lower than the control. \*\**p* < 0.01 vs control.



**Figure 4.** DNA fragmentation in oocytes was assessed using the TUNEL assay and propidium-iodide staining. Negative control oocytes were incubated only in the fluorescent solution lacking the enzyme to ensure the absence of labeling. Regarding the positive control, several oocytes were treated with the DNase I solution and then the TUNEL solution. Under a fluorescent microscope, oocytes were stained with a propidium iodide solution to identify their nuclei. All images are shown at x400 magnification.





**Figure 5.** The related gene expression of *GDF-9* in various groups. \*\* and \*indicate p < 0.001 and p < 0.01, respectively. GDF-9: growth differentiation factor 9, MDA: Melatonin, L: L-carnitine.



**Figure 6.** The related gene expression of *BMP-15* in various groups. \*\*\* *p* < 0.001, MDA: Melatonin, L: L-carnitine.

### **4. Discussion**

This study aimed to investigate the effects of supplementing the IVM culture medium with antioxidants on oocyte quality, maturation rate, and apoptosis index of the oocytes, as well as the expression levels of *GDF-9* and *BMP-15*. Oocyte quality is one of the critical factors in embryonic development, IVM, and subsequent female fertility (15). Oxidative homeostasis has been shown to be effective for the quality of oocytes (16). Supplementing the IVM with melatonin has

been shown to decrease the ROS level and inhibit apoptotic events in bovine, porcine, and human oocytes resulting in increasing their developmental potential (8, 17). It has also been demonstrated that L-carnitine supplementation during IVM of immature oocytes has also been demonstrated to improve the preimplantation developmental competence of oocytes due to cytoplasmic acceleration and nuclear maturation of oocytes (9). Supplementing the IVM with L-carnitine has been widely studied to increase the quality and maturity of oocytes in several mammalian species. Although the relationship between oocyte quality and the oocyte culture environments containing antioxidant and anti-apoptotic agents has been widely studied, the effects of the combination of melatonin and L-carnitine have not been studied. The results of this study indicated that both the oocyte quality and maturation were improved, and the apoptosis rate was decreased in all the treatment groups, especially in the melatonin + Lcarnitine groups and melatonin alone, compared to the control group. Individual oocytes were assessed based on TOS with 6 parameters, including size, morphology, cytoplasm, ZP, PVS, and PB. These 6 parameters are directly predictive of embryo quality (18). The results of gene expression showed that both *BMP-15* and *GDF-9* were significantly upregulated in all treatment groups compared to the control group. Both *BMP-15* and *GDF-9* have been demonstrated to affect folliculogenesis and oocyte quality. *GDF-9* contributes to follicular development and differentiation of GCs in mice. *BMP-15* has been shown to promote follicle maturation, regulate granulosa sensitivity to follicle-stimulating hormone action, increase oocyte developmental competence, and prevent granulosa apoptosis (19). The mRNAs of BMP-15 and GDF-9 proteins have been shown to express in female mice oocytes during folliculogenesis (20).

The present study's findings demonstrated no significant difference between the control and treatment groups in terms of oocyte diameter and PVS. It has been previously reported that melatonin cannot improve cumulus expansion and PVS formation (21). We have found that both melatonin and L-carnitine alone and in combination with melatonin, cannot alter oocyte diameter and PVS in IVM. To our knowledge, there is no study about the effect of L-carnitine alone and in combination with melatonin on oocyte diameter and PVS. All treatment groups oocyte morphology, cytoplasmic pattern, and PB morphology were predominantly graded as +1. Previous studies

have shown that oocytes derived from IVM have reduced developmental potential compared to those matured in vivo (22).

Moreover, poor oocyte quality plays a key role in female infertility (23). Oxidative stress is a phenomenon that occurs during the in vitro culture of oocytes since these oocytes are exposed to higher  ${\mathsf O}_2$  concentrations than those developing in vivo. Therefore, this increased oxidative stress is a burden for oocyte IVM. Consequently, application of antioxidants in these procedures seems to be essential (24).

L-carnitine is involved in fatty acid transportation into mitochondria for ATP synthesis via betaoxidation. L-carnitine improves oocyte quality and early embryo development by improving mitochondrial beta-oxidation (10). Oocytes do not produce L-carnitine during IVM (18), however, its metabolite has been found within follicular fluid (22). Despite its role as a radical scavenger (25) and a potent antioxidant (22), the addition of L-carnitine to the IVM medium of bovine oocytes had no significant effect on the development potential of the embryos (26).

The obtained results of the TUNEL assay indicated that adding L-carnitine and melatonin alone or in combination with each other to the IVM culture medium significantly reduced the apoptosis rate of oocytes compared to the control group, especially the melatonin + L-carnitine. These findings may result from reducing the ROS level and inhibiting apoptotic events of melatonin and L-carnitine (27). Moreover, in contrast with these results, it has been shown that L-carnitine does not affect DNA fragmentation (26).

A significant promotion in oocyte maturity using exposure to melatonin and L-carnitine alone and in combination compared to the control group was reported in the present study. The melatonin + L-carnitine group detected the highest maturity rate. It has been reported that melatonin improves the cytoplasmic maturity of oocytes (17) in which it induces overexpression of maturationrelated genes, *GDF-9*, and meiosis regulator and mRNA stability factor 1 (26), redistribution of organelles, and expression of antioxidant enzymes (17). Melatonin induces meiosis resumption, and oocytes treated with this compound are supported for subsequent development into an embryo (28). Melatonin enhances the quality of conditions required for embryo development. This is highly dependent on melatonin dosage, which, at low concentrations, may not be effective for improving embryo development, and at high concentrations, it may cause embryo damage; therefore, choosing a proper dosage for this compound is important. The reduction of ROS levels and apoptosis rate by melatonin favors promoting oocyte maturation. Melatonin, through its membrane receptors, can affect oocyte maturation. Melatonin membrane receptors, melatonin membrane receptor 1 and melatonin membrane receptor 2 are reported to be expressed in bovine oocytes (26). However, there is no similar study on the effect of L-carnitine on oocyte maturation.

In this study, the improvement of oocyte quality, maturation, and apoptosis rate in all treatment groups was consistent with the results of previous studies, which can be done through the antioxidant effects of melatonin and L-carnitine.

## **5. Conclusion**

Since the findings of the present study clearly and strongly indicate that combination therapy with melatonin and L-carnitine beneficially affects oocyte quality. Considering the higher efficacy of applying melatonin + L-carnitine compared to melatonin and L-carnitine alone, it would be presumed that the application of a combination of melatonin and Lcarnitine, favorably results in the promotion of oocyte quality and maturation rate. However, further research is still required for the in vitro promotion of oocyte maturation.

## **Data availability**

Data supporting the findings of this study are available upon reasonable request from the corresponding author.

### **Author contributions**

Raziye Chegini: Writing original draft, data collection, conceptualization. Morteza Sadeghi: Data curation, project administration. Sadegh Shirian: Writing, statistics. Fatemeh Sabbaghziarani: Drafting article. Ehsan Aali: Investigation, data analysis. Pouriya Soleimani: Data collection. Mohammad Reza Ashtari Majelan: Resources, data collection. Shahram Darabi: Writing, software. Fariba Zafari: Supervision, project administration.

### **Acknowledgments**

This work was supported by the Cellular and Molecular Research Center of Qazvin University of Medical Sciences, Qazvin, Iran (grant no: 28/20/14564). The authors have declared that they did not use artificial intelligence in this study.

### **Conflict of Interest**

The authors declared no potential conflict of interest with respect to the research, authorship, and/or publication of this article.

### **References**

- [1] Yalçınkaya E, Calışkan E, Budak O. In vitro maturation may prevent the cancellation of in vitro fertilization cycles in poor responder patients: A case report. *J Turk Ger Gynecol Assoc* 2013; 14: 235–237.
- [2] De Vos M, Grynberg M, Ho TM, Yuan Y, Albertini DF, Gilchrist RB. Perspectives on the development and future of oocyte IVM in clinical practice. *J Assist Reprod Genet* 2021; 38: 1265–1280.
- [3] Li W, Cheng K, Zhang Y, Meng Q, Zhu Se, Zhou G. No effect of exogenous melatonin on development of cryopreserved metaphase II oocytes in mouse. *J Anim Sci Biotechnol* 2015; 6: 42.
- [4] Budani MC, Tiboni GM. Effects of supplementation with natural antioxidants on oocytes and preimplantation embryos. *Antioxidants* 2020; 9: 612.
- [5] Belli M, Shimasaki S. Molecular aspects and clinical relevance of *GDF9* and *BMP15* in ovarian function. *Vitam Horm* 2018; 107: 317–348.
- [6] Sanfins A, Rodrigues P, Albertini DF. *GDF-9* and *BMP-15* direct the follicle symphony. *J Assist Reprod Genet* 2018; 35: 1741–1750.
- [7] Mortezaee K, Sabbaghziarani F, Omidi A, Dehpour AR, Omidi N, Ghasemi S, et al. Therapeutic value of melatonin post-treatment on CCl(4)-induced fibrotic rat liver. *Can J Physiol Pharmacol* 2016; 94: 119–130.
- [8] Loren P, Sánchez R, Arias ME, Felmer R, Risopatrón J, Cheuquemán C. Melatonin scavenger properties against oxidative and nitrosative stress: Impact on gamete handling and in vitro embryo production in humans and other mammals. *Int J Mol Sci* 2017; 18: 1119.
- [9] Zare Z, Masteri Farahani R, Salehi M, Piryaei A, Ghaffari Novin M, Fadaei Fathabadi F, et al. Effect of L-carnitine supplementation on maturation and early embryo development of immature mouse oocytes selected by brilliant cresyle blue staining. *J Assist Reprod Genet* 2015; 32: 635–643.
- [10] Li J, Liu L, Weng J, Yin TL, Yang J, Feng HL. Biological roles of l-carnitine in oocyte and early embryo development. *Mol Reprod Dev* 2021; 88: 673–685.
- [11] Gong X, Shen L, Zhang H, Ai J, Gilchrist RB, Zhao Y. CAPA-IVM improves the cytoplasmic quality of in vitro-matured oocytes from unstimulated mice. *Theriogenology* 2023; 212: 117–128.
- [12] Tadayoni S, Malekzadeh Shafarodi M, Ghasemi Hamidabadi H, Esmailnejad Moghaddam A, Khalilian A, Rezaei N. [Effect of combination of melatonin and all-trans retinoic acid on maturation, fertilization and embryonic development of immature mouse oocytes]. *J Gorgan Univ Med Sci* 2015; 17: 46–54. (in Persian)
- [13] Moawad AR, Salama A, Badr MR, Fathi M. Beneficial effects of L-carnitine supplementation during IVM of canine oocytes on their nuclear maturation and development in vitro. *Animals* 2021; 11: 581.
- [14] Lazzaroni-Tealdi E, Barad DH, Albertini DF, Yu Y, Kushnir VA, Russell H, et al. Oocyte scoring enhances embryo-scoring in predicting pregnancy chances with IVF where it counts most. *PloS One* 2015; 10: e0143632.
- [15] Xu HY, Yang XG, Lu SS, Liang XW, Lu YQ, Zhang M, et al. Treatment with acetyl-l-carnitine during in vitro maturation of buffalo oocytes improves oocyte quality and subsequent embryonic development. *Theriogenology* 2018; 118: 80–89.
- [16] Gupta S, Sekhon L, Kim Y, Agarwal A. The role of oxidative stress and antioxidants in assisted reproduction. *Current Women's Health Reviews* 2010; 6: 227–238.
- [17] Zhao XM, Wang N, Hao HS, Li CY, Zhao YH, Yan CL, et al. Melatonin improves the fertilization capacity and developmental ability of bovine oocytes by regulating cytoplasmic maturation events. *J Pineal Res* 2018; 64: e12455.
- [18] Kalehoei E, Moradi M, Azadbakht M, Zhaleh H, Parvini M, Cheraghbaeigi S, et al. In vitro maturation medium supplementation: Utilization of repaglinide, L-carnitine, and mesenchymal stem cell-conditioned medium to improve developmental competence of oocytes derived from endometriosis mouse models. *Braz J Med Biol Res* 2022; 55: e11948.
- [19] Shi XY, Jin XH, Lin JY, Sun LZ, Liu X, Zhang TY, et al. Idebenone relieves the damage of heat stress on the maturation and developmental competence of porcine oocytes. *Reprod Domest Anim* 2022; 57: 418–428.
- [20] Cadenas J, Pors SE, Kumar A, Kalra B, Kristensen SG, Andersen CY, et al. Concentrations of oocyte secreted *GDF9* and *BMP15* decrease with MII transition during human IVM. *Reprod Biol Endocrinol* 2022; 20: 126.
- [21] Farahavar A, Shahne A, Kohram H, Vahedi V. Effect of melatonin on in vitro maturation of bovine oocytes. *Afr J Biotechnol* 2010; 9: 2579–2583.
- [22] Dunning KR, Robker RL. The role of L-carnitine during oocyte in vitro maturation: Essential co-factor? Proceedings of the 31<sup>st</sup> Annual Meeting of the Brazilian Embryo Technology Society (SBTE); 2017 August 17–19; Brazil. *Anim Reprod* 2017; 14: 469–475.
- [23] Voiculescu SE, Zygouropoulos N, Zahiu CD, Zagrean AM. Role of melatonin in embryo fetal development. *J Med Life* 2014; 7: 488–492.
- [24] He B, Yin C, Gong Y, Liu J, Guo H, Zhao R. Melatonininduced increase of lipid droplets accumulation and in vitro maturation in porcine oocytes is mediated by mitochondrial quiescence. *J Cell Pysiolo* 2018; 233: 302–312.
- [25] Sprícigo JF, Morató R, Arcarons N, Yeste M, Dode MA, López-Bejar M, et al. Assessment of the effect of adding L-carnitine and/or resveratrol to maturation medium before vitrification on in vitro-matured calf oocytes. *Theriogenology* 2017; 89: 47–57.
- [26] Lin T, Lee J, Kang J, Kim S, Zhang J. The influence and role of melatonin on in vitro oocyte maturation and embryonic development in pig and cattle. *Korean J Agr Sci* 2017; 44: 309–317.
- [27] Mortezaee K, Pasbakhsh P, Kashani I, Sabbaghziarani F, Omidi A, Zendedel A, et al. Melatonin pretreatment enhances the homing of bone marrow-derived mesenchymal stem cells following transplantation in a rat model of liver fibrosis. *Iran Biomed J* 2016; 20: 207–216.
- [28] Rodrigues-Cunha MC, Mesquita LG, Bressan F, Collado MD, Balieiro JC, Schwarz KR, et al. Effects of melatonin during IVM in defined medium on oocyte meiosis, oxidative stress, and subsequent embryo development. *Theriogenology* 2016; 86: 1685–1694.